HLN:LSEHaleon PLC Analysis
Data as of 2026-03-10 - not real-time
£373.90
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Haleon plc trades at £373.9, just above its 200‑day SMA (£368.9) and the identified support level (£369.8), suggesting a technical floor that could hold in the near term. The stock is below its 20‑day (£398.3) and 50‑day (£384.7) moving averages and the MACD is bearish, yet the RSI of 38.9 points to oversold conditions and a potential short‑term bounce. Fundamentally, the company delivers strong margins (gross 64.7%, operating 22.9%) and a healthy free cash flow of £1.37 bn, while maintaining a modest payout ratio of 36.8% that supports the 1.88% dividend yield.
Valuation appears stretched: the DCF fair value is only £135.9 versus the market price, and the price‑to‑book ratio exceeds 200×, though the PE of 19.7 is below the industry average of 25.4, indicating relative earnings value. Debt‑to‑equity sits at 52.6% with ample cash, and analysts project a median target of £435, implying roughly 14% upside. The stock benefits from increasing volume and a low beta (‑0.06), but its 30‑day volatility is high at 31.9%.
Valuation appears stretched: the DCF fair value is only £135.9 versus the market price, and the price‑to‑book ratio exceeds 200×, though the PE of 19.7 is below the industry average of 25.4, indicating relative earnings value. Debt‑to‑equity sits at 52.6% with ample cash, and analysts project a median target of £435, implying roughly 14% upside. The stock benefits from increasing volume and a low beta (‑0.06), but its 30‑day volatility is high at 31.9%.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above support (£369.8) with rising volume
- RSI indicates oversold conditions that may trigger a bounce
- Bearish MACD and price below short‑term SMAs temper upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst median target of £435 suggests ~14% upside
- Strong cash generation and sustainable dividend yield
- Fundamentals (margins, ROE) remain robust despite flat revenue growth
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Resilient global consumer‑health brand portfolio
- Low sector and currency risk with diversified geographic exposure
- Stable dividend policy and manageable debt levels support long‑run stability
Key Metrics & Analysis
Financial Health
Revenue Growth0.60%
Profit Margin15.11%
P/E Ratio19.7
ROE10.27%
ROA4.65%
Debt/Equity52.62
P/B Ratio202.4
Op. Cash Flow£2.6B
Free Cash Flow£1.4B
Industry P/E25.4
Technical Analysis
TrendBullish
RSI38.9
Support£369.80
Resistance£416.10
MA 20£398.32
MA 50£384.68
MA 200£368.88
MACDBearish
VolumeIncreasing
Fear & Greed Index79.36
Valuation
Fair Value£135.94
Target Price£426.56
Upside/Downside14.08%
GradeOvervalued
TypeValue
Dividend Yield1.88%
Risk Assessment
Beta-0.06
Volatility31.93%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.